financetom
Business
financetom
/
Business
/
Airbus CEO hints at MBDA-like venture for European space merger
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Airbus CEO hints at MBDA-like venture for European space merger
Feb 20, 2025 3:15 AM

(Reuters) - The CEO of Airbus said on Thursday he would be happy if space merger talks with Thales and Leonardo led to a venture like the MBDA European missile project and hopes EU antitrust regulators will take a looser stance than in the past.

"We are looking at different scenarios... In Europe, we have technologies, even better ones (than in the US), but we are missing the scale that we need to be competitive," Guillaume Faury said during an earnings call.

MBDA, owned by Airbus, Britain's BAE Systems and Italy's Leonardo, was created in 2001 with the goal of making it one of the top global missile makers after a decade of military budget cuts across Europe that spurred sector consolidation.

Now, European firms are scrambling to remain competitive on space activities as demand in the commercial satellite market is shifting more towards low Earth orbit (LEO) constellations like the one owned by Elon Musk's Starlink, rather than traditional geostationary satellites.

"We really hope that the antitrust authorities of Europe will look at it in a different way compared to the past... that comes with creating consolidations that could look like a bit monopolistic in Europe," Faury told journalists at a press conference in Toulouse.

However, the CEO said that European firms are viewed as "small players" when compared to the "giants" in the U.S. and in China.

Earlier on Thursday, the world's largest planemaker reported a new 300 million euro ($313.20 million) charge for its troubled Space business.

Airbus has piled up almost 2 billion euros of total writedowns in two years for its satellite projects, which industry sources have mainly linked to its loss-making OneSat programme of reprogrammable satellites.

Last Friday satellite operator Eutelsat, an Airbus client with the British and the French government among its top investors, reported more than half a billion euros in impairment on GEO satellites.

($1 = 0.9579 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Couchbase to Be Acquired by Haveli Investments for $1.5 Billion
Couchbase to Be Acquired by Haveli Investments for $1.5 Billion
Jun 20, 2025
09:14 AM EDT, 06/20/2025 (MT Newswires) -- Couchbase ( BASE ) said Friday it has entered into a definitive agreement under which it will be acquired by Haveli Investments in an all-cash deal valued at about $1.5 billion. Under the deal terms, Couchbase ( BASE ) said its stockholders will receive $24.50 per share in cash. Once the transaction closes,...
BlackBerry's Valuation to Remain Discounted on 'Conservative' Guidance, RBC Says
BlackBerry's Valuation to Remain Discounted on 'Conservative' Guidance, RBC Says
Jun 20, 2025
09:16 AM EDT, 06/20/2025 (MT Newswires) -- BlackBerry's (BB) conservative guidance has set the bar low for fiscal Q1 earnings and the company's valuation is likely to remain discounted, pending improved visibility to sustained growth, RBC Capital Markets said in a Friday note. The company's fiscal Q1 results could exceed RBC's and consensus estimates, as the macro environment has been...
Actuate Therapeutics Identifies Biomarkers in Treatment of Metastatic Pancreatic Cancer in Phase 2 Trial
Actuate Therapeutics Identifies Biomarkers in Treatment of Metastatic Pancreatic Cancer in Phase 2 Trial
Jun 20, 2025
09:17 AM EDT, 06/20/2025 (MT Newswires) -- Actuate Therapeutics ( ACTU ) said Friday that its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer demonstrated the use of machine learning and statistical models to predict overall survival based on pre-dose plasma biomarkers. The analysis identified seven biomarkers as uniquely significant predictors of favorable survival...
Copyright 2023-2026 - www.financetom.com All Rights Reserved